Optimising adalimumab treatment in psoriasis with concomitant methotrexate. - OPTIMAP

Ghent University Hospital0 个研究点目标入组 100 人开始时间: 2015年4月8日最近更新: 2018年7月23日

适应症

试验速览

暂无简介。

•Have a diagnosis of moderate to severe plaque psoriasis (PASI=8 at time of screening);
•Is a candidate for the treatment with biologic drugs according to the pertaining guidelines;
•Willing and able to use an adequate contraceptives during the study (all men and pre-menopausal women);
•Adalimumab therapy will be started for the treatment of psoriasis
•Signed informed consent.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 4
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 2

•History of significant MTX or adalimumab toxicity, intolerability or contraindication
•Prior treatment with adalimumab
•Age < 18 years;
•Pregnant and nursing women.
•-other immunosuppressive medication (prednisone, mycofenolaatmofetyl (Cellcept e.g.), ciclosporine (Neoral e.g.), sirolimus (Rapamune), systemic tacrolimus (Prograft e.g.) e.g.)

发起方